The present study aims to assess the association between CYP2C19 SSRI inferred metaboliser status based on individual CYP2C19 polymorphisms and patient-reported efficacy of sertraline, citalopram and escitalopram in the Australian Genetics of Depression Study (AGDS). This evidence concerns the gene CYP2C19 and depressive symptom measurement.